JG
GALT icon

Jefferies Group’s Galectin Therapeutics GALT Stock Holding History

Jefferies Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26,800
Closed -$137K – 2644
2019
Q1 		$137K Buy
+26,800
New +$129K ﹤0.01% 2043
2018
Q2 		– Sell
-20,000
Closed -$95K – 2436
2018
Q1 		$95K Buy
+20,000
New +$93.2K ﹤0.01% 2067

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jefferies Group's GALT Position: Q2 2019 in Review

Jefferies Group sold out of Galectin Therapeutics (GALT) in Q2 2019, closing a stake of 26,800 shares — an estimated $137K sold.

Jefferies Group first reported a position in GALT in Q1 2018 and held it in 2 quarters. The position peaked at $137K in Q1 2019. 76 funds tracked by Wall St. Rank hold GALT as of Q2 2019.

  • Jefferies Group reported no remaining Galectin Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Jefferies Group sold 26,800 Galectin Therapeutics shares in Q2 2019, an estimated $137K.
  • Jefferies Group first reported a position in Galectin Therapeutics in Q1 2018 and held it in 2 quarters.
  • Jefferies Group's Galectin Therapeutics position peaked at $137K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.